SecBot SecBot
PRESS-RELEASE ·Filed May 7, 2026

BBIO

BridgeBio Pharma, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Monitor upcoming FDA decisions and PDUFA dates for BBP-418, encaleret, and infigratinib as key catalysts; the $500M buyback provides downside support but watch cash burn rate. EPS miss suggests higher-than-expected operating expenses may pressure near-term sentiment.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$67.39
T+0 close · May 7, 2026 · via day close
Latest settled
+21.78%
T+60 · $82.07
Vs SPY
+16.94%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $67.39entry
  2. T+1 · 6mo ago −4.02%α −4.25% · $64.68
  3. T+5 · 6mo ago +3.37%α +1.90% · $69.66
  4. T+20 · 5mo ago +0.33%α +0.30% · $67.61
  5. T+60 · 3mo ago +21.78%α +16.94% · $82.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio reported Q1 2026 revenue of $194.5M (beat $178.6M consensus) driven by $180.6M in Attruby sales, but EPS of -$0.84 missed the -$0.62 consensus. The company announced a $500M buyback and highlighted strong pipeline progress with upcoming NDAs. Mixed results as strong commercial execution is offset by higher costs and EPS miss.

Key Financial Metrics

EPS
−$0.84
est −$0.62 · -35.5%
Revenue
$194.5M
est $178.6M · +8.9% · +66.8% YoY
Rating
strong miss
Free Cash Flow
-$197.3M

Key Facts

  • Q1 2026 revenue $194.5M, +66.8% YoY, beat $178.6M consensus
  • Attruby U.S. net product revenue $180.6M vs $36.7M YoY
  • GAAP EPS -$0.84 vs consensus -$0.62 (miss of -35.5%)
  • Cash, cash equivalents and marketable securities $940.2M, up from $587.5M at Dec 2025
  • Board authorized $500M share repurchase program
  • Three NDAs planned: BBP-418 submitted, encaleret in 1H 2026, infigratinib in Q3 2026

Financial Impact

Revenue beat by $15.9M (8.9%), EPS miss by $0.22 (35.5%)

revenueepscash

Risk Factors

  • Regulatory delays or rejections for pipeline candidates
  • Competition from Pfizer's tafamidis (Vyndamax)
  • High operating cash burn of $197M in Q1 2026

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
97% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3290504

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (14h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026